EGFR and non-small cell lung carcinoma: The results of two phase III Japanese trials comparing gefitinib and chemotherapy as first-line treatment in NSCLC patients exclusively with tumours harbouring EGFR mutations confirmed improved outcomes with EGFR TKIs (Maemondo et al, 2010; Mitsudomi et al, 2010).